Clinical trial
Rifaximin Reduces the Complications of Decompensated Cirrhosis
NCT02190357 is registered in ClinicalTrials.gov with Shanghai Changzheng Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Rifaximin Reduces the Complications of Decompensated Cirrhosis
- Lead sponsor
- Shanghai Changzheng Hospital
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- August 31, 2014
- Completion date
- August 31, 2019
- Enrollment
- 200 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
cirrhosis